|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
A02 BA02
|
|
gptkbp:available_on
|
gptkb:tablet
gptkb:Sugar
Injection
|
|
gptkbp:brand
|
gptkb:Zantac
|
|
gptkbp:casnumber
|
66357-35-5
|
|
gptkbp:chemical_formula
|
C13 H12 N4 O3 S
|
|
gptkbp:clinical_trial
|
Ranitidine for GERD
Ranitidine for peptic ulcers
Ranitidine in children
Ranitidine safety profile
Ranitidine vs. placebo
|
|
gptkbp:contraindication
|
Hypersensitivity
Severe liver disease
|
|
gptkbp:discontinued
|
gptkb:2019
|
|
gptkbp:excretion
|
Urine
|
|
gptkbp:formulation
|
Injection 50 mg/2 ml
Syrup 15 mg/ml
Tablet 150 mg
Tablet 75 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ranitidine
|
|
gptkbp:interacts_with
|
gptkb:Ketoconazole
gptkb:Theophylline
gptkb:Warfarin
gptkb:Propranolol
|
|
gptkbp:lifespan
|
2-3 hours
|
|
gptkbp:mechanism_of_action
|
H2 receptor antagonist
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:related_to
|
gptkb:Famotidine
gptkb:Nizatidine
gptkb:Cimetidine
Antacids
Proton pump inhibitors
Histamine
Acid secretion
Gastric acid
|
|
gptkbp:replaces
|
gptkb:2019
|
|
gptkbp:route_of_administration
|
Intravenous
Oral
|
|
gptkbp:side_effect
|
gptkb:Nausea
Diarrhea
Dizziness
Fatigue
Headache
Constipation
|
|
gptkbp:used_for
|
gptkb:Zollinger-Ellison_syndrome
Gastroesophageal reflux disease
Peptic ulcer disease
|
|
gptkbp:bfsParent
|
gptkb:Sir_James_Black
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|